Reports Q1 revenue $12.95B, consensus $12.64B. CEO of Novartis, said: "Novartis delivered strong growth to start 2023, driven by our in-market growth brands, in particular Entresto, Kisqali and Kesimpta. The Pluvicto and Scemblix launches continue on their strong trajectory, and the Leqvio launch is progressing steadily. In addition, we are driving R&D productivity by prioritizing high-value medicines across our five core therapeutic areas. Our pipeline momentum gives us confidence in our growth outlook, highlighted by the NATALEE Phase 3 positive readout for Kisqali in early breast cancer, and we look forward to upcoming readouts for iptacopan in multiple indications and Pluvicto in earlier lines of therapy. Our strong start to the year and confidence in our growth drivers allow us to raise guidance for the full year 2023."
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on NVS:
- Novartis Gains after Better-than-Expected Q1 Results, Raises Outlook
- Novartis presents new five-year data on Kesimpta
- Legend Biotech price target raised to $85 from $75 at BTIG
- Novartis price target raised to CHF 91 from CHF 88 at Morgan Stanley
- Novartis price target raised to CHF 85 from CHF 80 at Barclays
